Pharmacology Quiz: Receptors And Signal Transduction

20 questions · exam conditions

0:00

Receptors And Signal TransductionQuestion 1 of 20

A new monoclonal antibody is developed to treat a cancer driven by an overactive receptor tyrosine kinase (RTK). The antibody binds to an extracellular epitope on the RTK, separate from the ligand-binding site. It effectively inhibits downstream signaling via the Ras-MAP kinase pathway, even in the presence of saturating concentrations of the growth factor ligand. Which of the following is the most plausible mechanism for this antibody's inhibitory action?

It acts as a competitive antagonist at the orthosteric ligand-binding site.

It prevents the ligand-induced receptor dimerization required for trans-autophosphorylation.

It penetrates the cell membrane to allosterically inhibit the intracellular kinase domain.

It directly chelates the ATP required for the kinase activity of the receptor.

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Receptors And Signal Transduction

Practice Receptors And Signal Transduction in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Receptors And Signal Transduction, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

It acts as a competitive antagonist at the orthosteric ligand-binding site.
It prevents the ligand-induced receptor dimerization required for trans-autophosphorylation. (correct answer)
It penetrates the cell membrane to allosterically inhibit the intracellular kinase domain.
It directly chelates the ATP required for the kinase activity of the receptor.

Explanation: The correct answer is B. A critical step in the activation of most receptor tyrosine kinases is ligand-induced dimerization, where two receptor monomers come together. This dimerization brings their intracellular kinase domains into close proximity, allowing them to phosphorylate each other (trans-autophosphorylation), which then serves as a docking site for downstream signaling proteins. A monoclonal antibody binding to the extracellular domain can sterically hinder this dimerization process, thus preventing receptor activation. A is incorrect because the stem states the antibody binds to an epitope separate from the ligand-binding site and is effective even at saturating ligand concentrations. C is incorrect as large protein molecules like antibodies cannot passively penetrate the cell membrane to reach intracellular targets. D is incorrect because the antibody acts extracellularly and has no mechanism to chelate intracellular ATP.

Question 2

Following its release from the endoplasmic reticulum via IP3-gated channels, calcium (Ca²⁺) exerts many of its intracellular effects by binding to a ubiquitous, small cytosolic protein. This protein then undergoes a conformational change that allows it to interact with and modulate the activity of various target enzymes, such as Ca²⁺/calmodulin-dependent protein kinases (CaMKs). What is this primary intracellular Ca²⁺-binding protein?

Calmodulin (correct answer)
Protein kinase C
Troponin C
Diacylglycerol

Explanation: This question tests your understanding of calcium signaling pathways, a fundamental mechanism in cellular pharmacology. When you encounter questions about intracellular calcium effects, think about the key mediator proteins that translate calcium signals into cellular responses. Calcium released from the endoplasmic reticulum needs a binding partner to exert most of its intracellular effects. Calmodulin (choice A) is the primary calcium-sensing protein in cells. When four calcium ions bind to calmodulin, it undergoes a dramatic conformational change that exposes hydrophobic regions, allowing it to bind and activate numerous target proteins including CaMKs, phosphodiesterases, and calcium pumps. This calcium-calmodulin complex is essentially the "on switch" for calcium-dependent processes. Choice B, protein kinase C, is actually activated by diacylglycerol and calcium together, but it's not the primary calcium-binding mediator protein described in the question. Choice C, troponin C, is a calcium-binding protein, but it's specifically found in skeletal and cardiac muscle for contraction regulation—not the "ubiquitous" protein mentioned. Choice D, diacylglycerol, isn't even a protein; it's a lipid second messenger that works alongside calcium in some pathways. For pharmacology exams, remember that calmodulin is the universal calcium translator in cells. When you see questions about calcium's intracellular effects, especially involving enzyme activation or calcium-dependent protein kinases, calmodulin is likely involved. Many drugs work by interfering with calcium-calmodulin interactions, making this a clinically relevant concept.

Question 3

A benzodiazepine is administered to a patient. This drug binds to the GABA-A receptor at a site distinct from the GABA binding site. In the presence of GABA, the benzodiazepine increases the frequency of chloride channel opening, leading to enhanced neuronal inhibition. Which of the following terms best describes the action of the benzodiazepine?

Competitive agonist
Non-competitive antagonist
Positive allosteric modulator (correct answer)
Inverse agonist

Explanation: The correct answer is C. The benzodiazepine binds to an allosteric site (a site other than the orthosteric site where the endogenous ligand, GABA, binds). It has little to no effect on its own but enhances the effect of the endogenous ligand when it is present. This is the definition of a positive allosteric modulator. A is incorrect because the drug does not bind to the primary agonist (GABA) site. B is incorrect because it enhances, rather than antagonizes, the effect of GABA. D is incorrect because an inverse agonist would decrease chloride flux, producing an effect opposite to that of GABA, which is not what benzodiazepines do at the GABA-A receptor.

Question 4

A researcher is studying two different neurotransmitter receptors in a neuronal culture. Activation of Receptor A with its ligand results in a membrane depolarization that begins within 2 milliseconds. Activation of Receptor B with its lipophilic steroid ligand results in the synthesis of new proteins, with a detectable functional change occurring after 4 hours. Which of the following pairs correctly identifies the most likely receptor superfamilies for Receptor A and Receptor B?

Receptor A: G-protein-coupled receptor; Receptor B: Enzyme-linked receptor
Receptor A: Ligand-gated ion channel; Receptor B: Intracellular receptor (correct answer)
Receptor A: Enzyme-linked receptor; Receptor B: G-protein-coupled receptor
Receptor A: Ligand-gated ion channel; Receptor B: G-protein-coupled receptor

Explanation: The correct answer is B. The time course of action is a key distinguishing feature of receptor superfamilies. Receptor A acts within milliseconds, which is characteristic of ligand-gated ion channels that directly open an ion pore upon ligand binding. Receptor B acts over hours and involves the synthesis of new proteins, which is the hallmark of intracellular (nuclear) receptors. These receptors are activated by lipophilic ligands (like steroids) that cross the cell membrane, and the ligand-receptor complex acts as a transcription factor to alter gene expression, a process that takes hours. A and C are incorrect because GPCRs (seconds to minutes) and enzyme-linked receptors (minutes to hours) have intermediate time courses and do not fit both descriptions. D is incorrect because the response time for Receptor B (hours) is far too long for a GPCR-mediated effect.

Question 5

Angiotensin II binds to the AT1 receptor, a Gq-protein-coupled receptor, on vascular smooth muscle cells. The activation of this receptor leads to vasoconstriction. Which of the following sequences correctly describes the initial intracellular signaling events immediately following Gq protein activation?

Activation of adenylyl cyclase → Increased cAMP → Activation of protein kinase A.
Activation of phospholipase C → Cleavage of PIP2 → Generation of IP3 and DAG. (correct answer)
Opening of receptor-operated calcium channels → Influx of extracellular Ca²⁺.
Inhibition of adenylyl cyclase → Decreased cAMP → De-inhibition of myosin light-chain kinase.

Explanation: The correct answer is B. The Gq alpha subunit, when activated, binds to and activates the enzyme phospholipase C (PLC). PLC then cleaves a membrane phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses to the endoplasmic reticulum to release stored Ca²⁺, and DAG, along with Ca²⁺, activates protein kinase C. A describes the Gs pathway. C describes one potential downstream effect of other pathways or receptor types, but it is not the initial event following Gq activation itself. D describes the Gi pathway.

Question 6

A scientist is investigating a partial agonist, Drug P, at a receptor that has a high degree of receptor reserve in a specific tissue. How would the maximal effect (Emax) and potency (EC50) of Drug P in this tissue likely compare to the properties of a full agonist, Drug F, in the same tissue?

Drug P will have a lower Emax and a lower EC50 (higher potency) than Drug F.
Drug P will have a lower Emax and a higher EC50 (lower potency) than Drug F.
Drug P will have an Emax equal to Drug F but a higher EC50 (lower potency). (correct answer)
Drug P will have an Emax equal to Drug F and an EC50 equal to Drug F.

Explanation: The correct answer is C. A partial agonist has lower intrinsic activity than a full agonist. However, in a system with a large receptor reserve (spare receptors), a partial agonist can often produce a maximal response (Emax equal to that of a full agonist) because it can activate a sufficient number of the excess receptors to saturate the downstream signaling pathway. Despite being able to achieve a full Emax, the partial agonist will require occupation of a greater fraction of receptors to do so compared to the full agonist. This means its concentration-response curve will be shifted to the right, reflecting a higher EC50 value (lower potency). A and B are incorrect because in a system with high reserve, the partial agonist can achieve the same Emax as the full agonist. D is incorrect because the partial agonist will be less potent (higher EC50) than the full agonist.

Question 7

Signal amplification is a key feature of many receptor-mediated pathways. In the G-protein-coupled receptor (GPCR) cascade, which of the following steps contributes least to the overall amplification of the initial signal?

A single receptor activating multiple G-proteins.
Adenylyl cyclase generating multiple cAMP molecules.
Protein kinase A phosphorylating multiple target proteins.
Binding of a single ligand molecule to a single receptor. (correct answer)

Explanation: The correct answer is D. Signal amplification occurs at enzymatic or catalytic steps in a cascade. The binding of one ligand to one receptor is a stoichiometric, 1:1 event and does not involve amplification. In contrast, the subsequent steps are catalytic: one activated receptor can activate multiple G-proteins before it is desensitized (A); one activated adenylyl cyclase molecule can generate hundreds or thousands of cAMP molecules (B); and one activated protein kinase A molecule can phosphorylate hundreds or thousands of substrate proteins (C). Therefore, the initial ligand-receptor binding event is the only step listed that is not a point of signal amplification.

Question 8

The cytokine receptor for erythropoietin lacks an intrinsic kinase domain. Upon binding of erythropoietin and receptor dimerization, it must recruit a cytosolic tyrosine kinase to initiate downstream signaling. Which of the following protein families is most likely recruited to and activated by the erythropoietin receptor?

Ras family of small GTPases
G-protein-coupled receptor kinases (GRKs)
Janus kinases (JAKs) (correct answer)
Protein kinase C (PKC) isoforms

Explanation: The correct answer is C. Receptors for many cytokines, including erythropoietin, belong to a superfamily that lacks intrinsic catalytic activity. These receptors function by associating with and activating cytosolic tyrosine kinases of the Janus kinase (JAK) family. Upon ligand-induced dimerization, the receptor-associated JAKs are brought into close proximity, allowing them to trans-phosphorylate and activate each other. The activated JAKs then phosphorylate the receptor itself, creating docking sites for STAT (Signal Transducer and Activator of Transcription) proteins, which mediate the downstream effects. A is incorrect because Ras is a downstream effector of receptor tyrosine kinases, not the kinase that associates with cytokine receptors. B is incorrect because GRKs phosphorylate GPCRs to promote desensitization. D is incorrect because PKC is activated by the Gq pathway second messengers DAG and Ca²⁺.

Question 9

In an isolated smooth muscle preparation, the concentration-response curve for a full agonist, Agonist X, is determined. The EC50, the concentration required to produce 50% of the maximal effect, is found to be 5 nM. Subsequent radioligand binding studies determine that the dissociation constant (Kd), the concentration at which 50% of the receptors are occupied, is 50 nM. Which of the following is the most accurate conclusion that can be drawn from this discrepancy?

Agonist X is a partial agonist with low intrinsic activity.
The tissue possesses a significant population of spare receptors. (correct answer)
A non-competitive antagonist was present in the muscle preparation.
The receptors for Agonist X are subject to rapid tachyphylaxis.

Explanation: The correct answer is B. The phenomenon where the EC50 is less than the Kd (EC50 < Kd) is the definition of the presence of spare receptors, also known as a receptor reserve. This means that a maximal physiological response can be achieved when only a fraction of the total receptors are occupied by the agonist. The cell has more receptors than are necessary to elicit a maximal response. A is incorrect because if Agonist X were a partial agonist, it would not be able to produce a maximal effect (Emax < 100%), which is not stated and does not explain the EC50/Kd relationship. C is incorrect because a non-competitive antagonist would decrease the maximal response (Emax) but would not necessarily cause the EC50 to be lower than the Kd. D is incorrect because tachyphylaxis describes a rapid decrease in response over time with repeated administration, not a static relationship between concentration, binding, and effect in a single experiment.

Question 10

It acts as a competitive antagonist at the orthosteric ligand-binding site.
It prevents the ligand-induced receptor dimerization required for trans-autophosphorylation. (correct answer)
It penetrates the cell membrane to allosterically inhibit the intracellular kinase domain.
It directly chelates the ATP required for the kinase activity of the receptor.

Question 11

A patient with a constitutively active mutant Gs-protein-coupled receptor is experiencing symptoms due to pathologically elevated intracellular cAMP levels. A new drug is administered that reduces the cAMP levels back towards baseline. This drug does not affect the binding of the endogenous agonist. Which of the following best describes this drug?

A competitive antagonist
A partial agonist
A non-competitive antagonist
An inverse agonist (correct answer)

Explanation: The correct answer is D. A constitutively active receptor is one that signals in the absence of an agonist. An inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. It stabilizes the receptor in an inactive conformation, thereby reducing its constitutive activity. In this case, the drug reduces the elevated cAMP levels, demonstrating an effect opposite to that of a typical agonist. A is incorrect because a competitive (or neutral) antagonist would block the effects of an agonist but would have no effect on the constitutive activity of the receptor itself. B is incorrect because a partial agonist would still activate the receptor, albeit submaximally, and would likely increase or at least not decrease the already elevated cAMP levels. C is incorrect for the same reason as A; a classical non-competitive antagonist would prevent agonist activation but not reduce constitutive activity.

Question 12

A cardiac myocyte expresses both β1-adrenergic receptors (Gs-coupled) and M2 muscarinic receptors (Gi-coupled). Simultaneous stimulation of the myocyte with a β1 agonist and an M2 agonist would result in which of the following net effects on adenylyl cyclase activity?

An attenuated level of activation compared to the β1 agonist alone. (correct answer)
A supra-additive synergistic activation.
Complete inhibition, regardless of agonist concentrations.
Activation of a separate isoform of adenylyl cyclase via the Gi pathway.

Explanation: When you encounter questions about opposing G-protein coupled receptor (GPCR) pathways, focus on how Gs and Gi proteins create competing effects on the same target enzyme, adenylyl cyclase. β1-adrenergic receptors couple to Gs proteins, which activate adenylyl cyclase to increase cAMP production. M2 muscarinic receptors couple to Gi proteins, which inhibit adenylyl cyclase and decrease cAMP formation. When both receptors are stimulated simultaneously, you're looking at a classic case of functional antagonism at the adenylyl cyclase level. The correct answer is A because the Gi-coupled M2 receptors will partially counteract the Gs-mediated activation from β1 receptors. The net result is adenylyl cyclase activation that's weaker than what you'd see with β1 stimulation alone - hence "attenuated activation." Answer B is wrong because these pathways oppose each other rather than synergize. Synergism would require both pathways to enhance the same downstream effect. Answer C incorrectly suggests complete inhibition, but Gi doesn't completely shut down adenylyl cyclase - it competes with Gs activation. The net effect depends on the relative strengths of both signals. Answer D misunderstands the mechanism; Gi doesn't activate adenylyl cyclase at all, let alone a different isoform. Remember this pattern: when Gs and Gi pathways target the same enzyme simultaneously, the result is always modulation (enhancement or attenuation) rather than complete inhibition or synergism. The dominant effect depends on receptor expression levels and agonist concentrations.

Question 13

A patient has been on long-term therapy with a high dose of a competitive antagonist for a specific GPCR. If the antagonist is abruptly discontinued, the patient experiences an exaggerated, hypersensitive response to the endogenous ligand for that receptor. What is the most likely cellular mechanism underlying this phenomenon?

Downregulation of the target receptors.
Increased rate of metabolism of the endogenous ligand.
Upregulation of the target receptors. (correct answer)
Permanent covalent modification of the G-protein.

Explanation: The correct answer is C. Chronic blockade of receptors with an antagonist can lead to a compensatory cellular response known as upregulation. The cell synthesizes more receptors and inserts them into the cell membrane in an attempt to overcome the blockade and restore normal signaling levels. When the antagonist is abruptly withdrawn, this increased number of receptors is now fully available to be stimulated by the endogenous ligand, leading to an exaggerated or hypersensitive response. A is incorrect; downregulation (a decrease in receptor number) is typically seen with chronic agonist stimulation. B is incorrect because receptor antagonism does not typically induce changes in ligand metabolism. D is incorrect because G-protein modifications related to signaling are transient, not permanent, and this does not explain the change in receptor sensitivity.

Question 14

Ras family of small GTPases
G-protein-coupled receptor kinases (GRKs)
Janus kinases (JAKs) (correct answer)
Protein kinase C (PKC) isoforms

Question 15

The glucocorticoid receptor is a member of the nuclear receptor superfamily. In its inactive state, where is this receptor predominantly located within the cell, and what protein is it typically complexed with?

In the nucleus, complexed with co-repressor proteins.
In the plasma membrane, complexed with a G-protein.
In the cytosol, complexed with heat shock proteins (HSPs). (correct answer)
In the endoplasmic reticulum, complexed with chaperone proteins.

Explanation: The correct answer is C. Unlike Type I steroid receptors (e.g., for thyroid hormone) which are often already in the nucleus, Type II receptors like the glucocorticoid receptor reside in the cytosol in their inactive state. They are maintained in a conformation ready for ligand binding by being complexed with a chaperone protein complex, most notably heat shock protein 90 (HSP90). Upon binding of the lipophilic glucocorticoid ligand, the receptor undergoes a conformational change, dissociates from the HSPs, dimerizes, and translocates into the nucleus to act as a transcription factor. A describes the state of some other nuclear receptors, but not the glucocorticoid receptor. B is incorrect as this is a nuclear receptor, not a GPCR. D is incorrect location and complex, though HSPs are a type of chaperone.

Question 16

Activation of a Gq-coupled receptor leads to the generation of two second messengers, inositol trisphosphate (IP3) and diacylglycerol (DAG). While these are generated from the same precursor molecule, they have distinct downstream actions. What are the primary, immediate targets of IP3 and DAG, respectively?

IP3 opens calcium channels on the endoplasmic reticulum; DAG activates protein kinase C. (correct answer)
IP3 activates protein kinase C; DAG opens calcium channels on the endoplasmic reticulum.
Both IP3 and DAG converge to activate protein kinase A.
IP3 activates calmodulin; DAG activates a MAP kinase cascade.

Explanation: When you encounter questions about Gq-coupled receptors, focus on the phospholipase C (PLC) pathway and how it generates two distinct second messengers from a single precursor molecule, PIP₂ (phosphatidylinositol 4,5-bisphosphate). Here's how the pathway works: Gq activation triggers PLC, which cleaves PIP₂ into IP₃ and DAG. These molecules then diverge to create separate signaling cascades. IP₃ is water-soluble and diffuses through the cytoplasm to bind IP₃ receptors on the endoplasmic reticulum, causing calcium release from intracellular stores. Meanwhile, DAG remains membrane-bound and directly activates protein kinase C (PKC), which then phosphorylates various target proteins. Answer A correctly identifies both targets: IP₃ opens ER calcium channels, and DAG activates PKC. Answer B reverses these roles—a common mistake since both molecules work in the same pathway. This reversal is incorrect because IP₃ lacks the ability to activate PKC (it's the wrong shape and location), while DAG cannot interact with ER calcium channels. Answer C suggests both messengers activate protein kinase A, but PKA is part of the cAMP pathway (Gs-coupled receptors), not the PLC pathway. Answer D incorrectly states that IP₃ activates calmodulin—calmodulin is actually activated by the calcium that IP₃ releases, not by IP₃ directly. Remember this sequence: Gq → PLC → PIP₂ cleavage → IP₃ (calcium release) + DAG (PKC activation). The key is that one precursor creates two messengers with completely different cellular targets.

Question 17

A patient with heart failure is treated with a β-adrenergic agonist. Initially, the drug improves cardiac contractility, but its effect diminishes over several hours despite continuous infusion. This rapid loss of efficacy is primarily initiated by the phosphorylation of the intracellular domains of the β-adrenergic receptor by G-protein-coupled receptor kinase (GRK). This phosphorylation directly facilitates the binding of which of the following proteins to promote receptor desensitization?

The Gs α-subunit, which uncouples from the receptor upon activation.
Protein kinase A, which is activated downstream of cAMP production.
β-arrestin, which sterically hinders G-protein coupling and promotes internalization. (correct answer)
Phosphodiesterase, which degrades the second messenger cAMP.

Explanation: The correct answer is C. Homologous desensitization of GPCRs, like the β-adrenergic receptor, involves a multi-step process. Upon prolonged agonist stimulation, G-protein-coupled receptor kinase (GRK) phosphorylates the receptor's intracellular loops. This phosphorylated receptor then serves as a high-affinity binding site for β-arrestin. The binding of the bulky β-arrestin protein sterically prevents the receptor from coupling to its G-protein (Gs), thus uncoupling it from signal transduction. β-arrestin also acts as an adaptor protein to recruit clathrin, initiating receptor-mediated endocytosis and internalization, further reducing the number of available receptors on the cell surface. A is incorrect because the Gs α-subunit dissociates from the receptor as part of the activation cycle, it does not bind to the phosphorylated receptor to cause desensitization. B is incorrect because while Protein Kinase A (PKA) can also phosphorylate the receptor (heterologous desensitization), the protein that binds after GRK phosphorylation to mediate uncoupling and internalization is β-arrestin. D is incorrect because phosphodiesterase degrades cAMP in the cytoplasm; it does not bind to the receptor.

Question 18

In the nucleus, complexed with co-repressor proteins.
In the plasma membrane, complexed with a G-protein.
In the cytosol, complexed with heat shock proteins (HSPs). (correct answer)
In the endoplasmic reticulum, complexed with chaperone proteins.

Question 19

Drug P will have a lower Emax and a lower EC50 (higher potency) than Drug F.
Drug P will have a lower Emax and a higher EC50 (lower potency) than Drug F.
Drug P will have an Emax equal to Drug F but a higher EC50 (lower potency). (correct answer)
Drug P will have an Emax equal to Drug F and an EC50 equal to Drug F.

Question 20

Activation of adenylyl cyclase → Increased cAMP → Activation of protein kinase A.
Activation of phospholipase C → Cleavage of PIP2 → Generation of IP3 and DAG. (correct answer)
Opening of receptor-operated calcium channels → Influx of extracellular Ca²⁺.
Inhibition of adenylyl cyclase → Decreased cAMP → De-inhibition of myosin light-chain kinase.